N
IKT icon

Nuveen’s Inhibikase Therapeutics IKT Stock Holding History

Nuveen’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$794K Buy
472,399
+393,740
+501% +$699K ﹤0.01% 2676
2025
Q4 		$161K Hold
78,659
– – ﹤0.01% 3179
2025
Q3 		$127K Hold
78,659
– – ﹤0.01% 3211
2025
Q2 		$153K Buy
+78,659
New +$154K ﹤0.01% 3207

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Nuveen's IKT Position: Q1 2026 in Review

Nuveen increased its Inhibikase Therapeutics (IKT) stake by 501% in Q1 2026, buying an estimated $699K and bringing the position to 472,399 shares worth $794K. The position accounts for ﹤0.01% of the portfolio, ranked #2676.

Nuveen first reported a position in IKT in Q2 2025 and has held it in 4 quarters since. 104 funds tracked by Wall St. Rank hold IKT as of Q1 2026.

  • Nuveen held 472,399 shares of Inhibikase Therapeutics worth $794K as of Q1 2026.
  • Nuveen bought 393,740 Inhibikase Therapeutics shares in Q1 2026, an estimated $699K.
  • Inhibikase Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #2676 holding.
  • Nuveen first reported a position in Inhibikase Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 104 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.